346 related articles for article (PubMed ID: 36291669)
1. An Overview of Molecular Mechanisms in Fabry Disease.
Amodio F; Caiazza M; Monda E; Rubino M; Capodicasa L; Chiosi F; Simonelli V; Dongiglio F; Fimiani F; Pepe N; Chimenti C; Calabrò P; Limongelli G
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291669
[TBL] [Abstract][Full Text] [Related]
2. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
3. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583
[TBL] [Abstract][Full Text] [Related]
4. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
5.
Kytidou K; Beekwilder J; Artola M; van Meel E; Wilbers RHP; Moolenaar GF; Goosen N; Ferraz MJ; Katzy R; Voskamp P; Florea BI; Hokke CH; Overkleeft HS; Schots A; Bosch D; Pannu N; Aerts JMFG
J Biol Chem; 2018 Jun; 293(26):10042-10058. PubMed ID: 29674318
[TBL] [Abstract][Full Text] [Related]
6. Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions.
Kok K; Zwiers KC; Boot RG; Overkleeft HS; Aerts JMFG; Artola M
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33673160
[TBL] [Abstract][Full Text] [Related]
7. An expert consensus document on the management of cardiovascular manifestations of Fabry disease.
Linhart A; Germain DP; Olivotto I; Akhtar MM; Anastasakis A; Hughes D; Namdar M; Pieroni M; Hagège A; Cecchi F; Gimeno JR; Limongelli G; Elliott P
Eur J Heart Fail; 2020 Jul; 22(7):1076-1096. PubMed ID: 32640076
[TBL] [Abstract][Full Text] [Related]
8. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic advances in Fabry disease: The future awaits.
Kant S; Atta MG
Biomed Pharmacother; 2020 Nov; 131():110779. PubMed ID: 33152937
[TBL] [Abstract][Full Text] [Related]
10. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
11. Treatment of fabry disease: current and emerging strategies.
Rozenfeld P; Neumann PM
Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
Duro G; Zizzo C; Cammarata G; Burlina A; Burlina A; Polo G; Scalia S; Oliveri R; Sciarrino S; Francofonte D; Alessandro R; Pisani A; Palladino G; Napoletano R; Tenuta M; Masarone D; Limongelli G; Riccio E; Frustaci A; Chimenti C; Ferri C; Pieruzzi F; Pieroni M; Spada M; Castana C; Caserta M; Monte I; Rodolico MS; Feriozzi S; Battaglia Y; Amico L; Losi MA; Autore C; Lombardi M; Zoccali C; Testa A; Postorino M; Mignani R; Zachara E; Giordano A; Colomba P
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477121
[TBL] [Abstract][Full Text] [Related]
13. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
Chen Z; Yin B; Jiao J; Ye T
BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
[TBL] [Abstract][Full Text] [Related]
14. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
[TBL] [Abstract][Full Text] [Related]
15. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.
Choi JB; Seol DW; Do HS; Yang HY; Kim TM; Byun YG; Park JM; Choi J; Hong SP; Chung WS; Suh JM; Koh GY; Lee BH; Wee G; Han YM
Mol Ther; 2023 Apr; 31(4):1002-1016. PubMed ID: 36755495
[TBL] [Abstract][Full Text] [Related]
16. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
17. Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse.
Cortés-Saladelafont E; Fernández-Martín J; Ortolano S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982318
[TBL] [Abstract][Full Text] [Related]
18. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
Labilloy A; Youker RT; Bruns JR; Kukic I; Kiselyov K; Halfter W; Finegold D; do Monte SJ; Weisz OA
Mol Genet Metab; 2014 Feb; 111(2):184-92. PubMed ID: 24215843
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the GLA gene in Mexican families with Fabry disease.
Gutiérrez-Amavizca BE; Gal A; Ortíz-Orozco R; Orth U; Prado Montes De Oca E; Gutiérrez-Amavizca JP; Figuera LE
J Genet; 2017 Mar; 96(1):161-164. PubMed ID: 28360401
[TBL] [Abstract][Full Text] [Related]
20. The heart in Fabry's disease.
Sheppard MN
Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
